+0.72 (+5.47%)
Dilution Risk
R&D Expenses
1.46 M
Operating CF
-2.49 M
Total Assets
33.89 M
Total Liabilities
19.51 M
Equity
14.38 M
D/E Ratio
12,345
Cash Position
2.77 M
Monthly Burn
829.00 K
Runway
1.8 mo
Burn Trend
StableSEC Filing
May 19, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Dated clinical, regulatory & corporate events for Akari Therapeutics Plc
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rVA576 Small molecule | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | NCT03588026 | 50% | $361M | COMPLETED | 9 | - | - | Sep 3, 2020 | - | Apr 9, 2025 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Trastuzumab-PH1 | — | — | 2025-11-10 | In preclinical studies, the combination of Trastuzumab-PH1 and anti-PD1 therapy resulted in a complete response rate of 74%, significantly higher than the 42% observed with Kadcyla® plus anti-PD1 (p<0.05), demonstrating enhanced anti-tumor immunity. Read More | Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors Read More | |
Trastuzumab-PH1 | — | — | 2025-11-10 | In preclinical studies, the combination of Trastuzumab-PH1 and anti-PD1 therapy resulted in a complete response rate of 74%, significantly higher than the 42% observed with Kadcyla® plus anti-PD1 (p<0.05), demonstrating enhanced anti-tumor immunity. Read More | Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors Read More | |
Trastuzumab-PH1 | — | — | 2025-11-10 | In preclinical studies, the combination of Trastuzumab-PH1 and anti-PD1 therapy resulted in a complete response rate of 74%, significantly higher than the 42% observed with Kadcyla® plus anti-PD1 (p<0.05), demonstrating enhanced anti-tumor immunity. Read More | Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Akari Therapeutics has appointed Dr. Patricia LoRusso to its Scientific Advisory Board, enhancing its expertise in oncology drug development. Dr. LoRusso's extensive experience will support the advancement of Akari's lead candidate, AKTX-101, which is set to enter a Phase 1 clinical trial. The company aims to leverage its novel RNA splicing modulator payload for impactful cancer therapies.
Read more →Akari Therapeutics has appointed Dr. Patricia LoRusso to its Scientific Advisory Board, enhancing its expertise as it prepares for the Phase 1 trial of AKTX-101. Dr. LoRusso brings over 25 years of experience in oncology and drug development, which will be crucial for advancing Akari's novel ADC payload targeting RNA splicing. The company aims to start its first-in-human trial by mid-2027.
Read more →Akari Therapeutics has completed its previously announced PIPE, consolidating investment closings into a single event, raising approximately $8.3 million. This funding will support the advancement of AKTX-101 towards a Phase 1 clinical trial and the development of its proprietary PH1 RNA splicing modulator ADC payload. The company aims to initiate its first-in-human trial by mid-2027.
Read more →The article announces the upcoming Annual General Meeting (AGM) of shareholders for AKTX, scheduled for June 30, 2026. It includes links to the proxy form and the annual report with consolidated financial statements for the year ended December 31, 2025. This meeting is an important event for shareholders to review company performance and future plans.
Read more →Akari Therapeutics' CEO, Abizer Gaslightwala, discusses the company's advancements in antibody drug conjugates (ADCs) during the 2026 ASCO Annual Meeting. He highlights the significance of novel payload technologies, particularly the PH1 spliceosome-modulating platform, in treating KRAS-driven cancers. Akari's upcoming Phase 1 trial for AKTX-101 is anticipated by mid-2027, showcasing the company's commitment to innovation in oncology.
Read more →Akari Therapeutics announced the acceptance of its abstract at the 2026 ASCO Annual Meeting, highlighting the synergy of its lead candidate AKTX-101 with adagasrib in treating KRAS-driven cancers. CEO Abizer Gaslightwala emphasized the importance of this milestone and the potential of their novel spliceosome-modulating ADC platform. The company plans to initiate a Phase 1 clinical trial by mid-2027.
Read more →Akari Therapeutics announced promising preclinical data for AKTX-101, an ADC with a novel RNA spliceosome modulating payload, showing synergistic effects when combined with a KRAS inhibitor in pancreatic cancer models. This data, presented at ASCO 2026, highlights the potential of AKTX-101 to enhance treatment efficacy for KRAS-driven cancers. The findings suggest that RNA splicing modulation could be a viable therapeutic strategy.
Read more →Akari Therapeutics has announced a successful private placement financing round expected to raise approximately $5.5 million. The funds will be utilized to advance its lead antibody drug conjugate, AKTX-101, toward a first-in-human Phase 1 clinical trial. The offering includes unregistered American Depository Shares and warrants, with proceeds aimed at working capital and corporate purposes.
Read more →Akari Therapeutics will present at A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026. CEO Abizer Gaslightwala will discuss the company's ADC pipeline, including the lead program AKTX-101, which targets cancer cells with a novel RNA splicing modulator payload. The company aims to initiate its First-In-Human trial by mid-2027.
Read more →Akari Therapeutics has been granted a significant European patent for its novel RNA splicing modulator payload, enhancing its global intellectual property portfolio. The patent, which covers Thailanstatin-based payloads for antibody drug conjugates (ADCs), supports the development of targeted therapies across multiple tumor types. This milestone is expected to bolster Akari's ADC pipeline, including lead candidate AKTX-101, which is set to enter clinical trials by mid-2027.
Read more →Akari Therapeutics has announced the acceptance of an Australian patent for its proprietary Thailanstatin analog payload used in antibody-drug conjugates (ADCs) aimed at treating cancer. This patent broadens Akari's global intellectual property portfolio and supports the development of its ADC candidates, including AKTX-101, which is targeting TROP2. The strengthening of its IP underscores Akari's strategy to establish a competitive edge in the ADC market, which is projected to grow significantly in the coming years. The company aims to advance its lead program into human trials by late 2026 or early 2027.
Read more →Akari Therapeutics announced the acceptance of its abstract for the 2026 ASCO Annual Meeting, marking its first entry into this prestigious oncology forum. The abstract discusses AKTX-101, an antibody-drug conjugate targeting KRAS-mutated tumors, and highlights its potential therapeutic synergy with a K-RAS inhibitor. The company aims to advance AKTX-101 into Phase 1 clinical trials by late 2026 or early 2027. This milestone complements Akari's focus on innovative cancer treatments leveraging novel RNA splicing modulation.
Read more →Akari Therapeutics announced positive preclinical data for AKTX-101, a TROP2-targeting antibody drug conjugate, at the AACR Annual Meeting 2026. This data indicates that AKTX-101 exhibits superior potency compared to existing TROP2 ADCs using Topoisomerase I inhibitors across various cancer types. The novel payload may provide an effective solution against drug resistance, potentially leading to improved patient outcomes. With the projected growth of the TROP2 ADC market, Akari is poised to advance AKTX-101 into clinical trials by early 2027.
Read more →Akari Therapeutics has announced a strategic partnership with WuXi XDC to enhance its development capabilities for antibody drug conjugates (ADCs). CEO Abizer Gaslightwala highlighted the partnership's role in accelerating the IND timeline for AKTX-101, with an expected filing in late 2026. The collaboration aims to strengthen Akari's position in the evolving ADC market and reduce execution risks.
Read more →Akari Therapeutics has formed a strategic partnership with WuXi XDC to expedite the development of its novel ADC payload, PH1, targeting RNA splicing. This collaboration aims to advance Akari's lead program, AKTX-101, which is focused on treating metastatic urothelial cancer. The partnership is expected to facilitate the filing of an IND by late 2026, with clinical trials anticipated to begin shortly thereafter.
Read more →Akari Therapeutics has entered a strategic partnership with WuXi XDC to expedite the development of its novel antibody drug conjugate (ADC) payload known as PH1, targeting RNA splicing. The collaboration aims to enhance the clinical progression of Akari's lead candidate, AKTX-101, which is focused on treating metastatic urothelial cancer. The initiative highlights the innovative mechanism of PH1, which has shown strong efficacy in preclinical studies. Akari plans to initiate Phase 1 clinical trials for AKTX-101 by late 2026 or early 2027, contingent upon regulatory approval.
Read more →Akari Therapeutics has announced that its abstract regarding the development of a differentiated Trop2 antibody-drug conjugate has been accepted for a poster presentation at the American Association for Cancer Research Annual Meeting 2026. The presentation will take place on April 20, 2026, focusing on targeting vulnerabilities in solid tumors. This acceptance highlights the ongoing innovative research by Akari in the oncology space, particularly their novel treatment approaches. The conference provides an opportunity for Akari to showcase their findings and establish connections within the oncology community.
Read more →Akari Therapeutics announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective March 31, 2026. The new ratio will increase from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares. This strategy is aimed at ensuring compliance with Nasdaq's minimum bid price requirement. Additionally, Akari is advancing its lead candidate, AKTX-101, which has shown promise in preclinical studies and may enhance cancer treatment outcomes, in preparation for First-In-Human trials set for late 2026/early 2027.
Read more →Akari Therapeutics announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective March 31, 2026. The new ratio will be one ADS representing eighty thousand ordinary shares, aimed at maintaining compliance with Nasdaq's minimum bid price requirement. This change requires ADS holders to exchange forty ADSs for one new ADS, with no fractional new ADSs issued.
Read more →Akari Therapeutics, under CEO Abizer Gaslightwala, has made significant strategic progress, particularly with its lead program AKTX-101, an ADC targeting Trop2. The company is preparing for clinical trials with plans to submit an IND or CTA by late 2026 or early 2027. Additionally, Akari has expanded its pipeline with AKTX-102 and strengthened its intellectual property through multiple patent filings.
Read more →Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology as it advances AKTX-101 towards clinical trials. Dr. Gokhale's extensive background in RNA biology and experimental therapeutics is expected to strengthen the development of Akari's novel ADCs. The company aims to initiate first-in-human trials for AKTX-101 by late 2026 or early 2027.
Read more →Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research. Dr. Anczukow's background in RNA splicing and therapeutic development is expected to support Akari's innovative approach to antibody drug conjugates. The company aims to leverage her insights to advance its PH1 ADC payload targeting cancer cells.
Read more →Akari Therapeutics will present at the 2026 Biocom Global Partnering & Investor Conference, highlighting its innovative antibody drug conjugates. CEO Abizer Gaslightwala will speak on February 25, 2026, at 11:00 AM PST. The company is focused on developing ADCs with unique payloads, particularly AKTX-101, which has shown promising preclinical results.
Read more →Akari Therapeutics will present at the 2026 Biocom Global Partnering & Investor Conference on February 25, 2026. CEO Abizer Gaslightwala will discuss the company's innovative antibody drug conjugates, particularly AKTX-101, which targets cancer cells with a novel payload. The company aims to start First-In-Human trials for AKTX-101 by late 2026 or early 2027.
Read more →Akari Therapeutics announced an expansion of its antibody drug conjugate (ADC) pipeline, including the introduction of AKTX-102. CEO Abizer Gaslightwala discussed the company's innovative PH1 payload and its lead program, AKTX-101, which is advancing towards IND and CTA submissions. The interview emphasized the strategic importance of Akari's growing patent estate.
Read more →Akari Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026. CEO Abizer Gaslightwala will present the company's next-generation antibody drug conjugate platform and discuss the lead program AKTX-101, which targets tumors with minimal off-target effects. The presentation will also cover ongoing IND-enabling activities for a first-in-human trial expected in late 2026 or early 2027.
Read more →Akari Therapeutics has filed a U.S. provisional patent for its second ADC candidate, AKTX-102, which targets CEACAM5, a challenging oncology target. This development is part of the company's strategy to expand its ADC pipeline and patent estate. The PH1 spliceosome payload used in AKTX-102 aims to enhance cytotoxic efficacy and activate immune responses against solid tumors. Akari's growing patent portfolio is expected to support the advancement of multiple ADC candidates.
Read more →Akari Therapeutics has released a CEO Corner segment detailing its progress in 2025 and plans for clinical transition in 2026. The company is advancing its novel antibody drug conjugate, AKTX-101, utilizing the PH1 payload, which has shown promising preclinical results. A strategic partnership with WuXi Biologics supports its clinical readiness, with plans to initiate a First-in-Human trial by late 2026.
Read more →Akari Therapeutics will present at the 2026 Biotech Showcase on January 13, 2026. CEO Abizer Gaslightwala will discuss the company's ADC platform and strategic priorities. Akari's lead candidate, AKTX-101, shows promise in targeting cancer cells with minimal off-target effects. The company aims to initiate its First-In-Human trial by late 2026 or early 2027.
Read more →Akari Therapeutics released a letter to shareholders detailing its progress in 2025, highlighting advancements in its antibody drug conjugate (ADC) technology, particularly the PH1 payload. The company has initiated GMP manufacturing for its lead program, AKTX-101, and is preparing for Phase 1 clinical trials. Akari anticipates 2026 to be a pivotal year with key milestones that could enhance its value and impact in oncology.
Read more →Akari Therapeutics has begun GMP manufacturing of AKTX-101 to support its Phase 1 clinical trial. The company has partnered with WuXi XDC, a leader in ADC manufacturing, to ensure high-quality production. AKTX-101 features a novel payload, PH1, which may enhance therapeutic effects against cancer. The trial is expected to start in late 2026 or early 2027, pending regulatory approval.
Read more →Akari Therapeutics announced that CEO Abizer Gaslightwala participated in a Virtual Investor segment titled "What This Means." During the segment, he discussed the company's novel payload, PH1, and highlighted promising preclinical data for their lead antibody drug conjugate, AKTX-101, specifically targeting hard-to-treat KRAS-mutant pancreatic cancer. Akari aims to advance this molecule towards clinical testing by late 2026 or early 2027, indicating their proactive approach in oncology biotechnology. The company is optimistic about the therapeutic potential of AKTX-101 and its implications for treating various difficult cancers.
Read more →Akari Therapeutics has announced a $5 million financing through a combination of a registered direct offering and a private placement priced at-market. The offering involves the issuance of approximately 12.6 million American Depositary Shares (ADSs) and includes significant participation from the company's Directors and Executive Management. The proceeds are intended for ongoing research and development as well as general corporate purposes. The closing of the offering is expected around December 17, 2025, subject to customary closing conditions.
Read more →Akari Therapeutics has announced promising preclinical data for its lead candidate, AKTX-101, showing its ability to target and kill K-Ras G12V mutant pancreatic cancer cells. The mutation is prevalent in a severe form of pancreatic cancer, which currently has very limited treatment options. The data indicates significant efficacy of AKTX-101, outperforming existing therapies in preclinical studies. The company plans to advance AKTX-101 towards first-in-human trials by late 2026, aiming to address a critical unmet need in oncology.
Read more →Akari Therapeutics, an oncology biotechnology company, has released a new CEO Corner segment detailing recent advancements. The company is promoting its ADC payload technology, especially the lead candidate AKTX-101, which targets the Trop2 receptor on cancer cells. The novel PH1 payload has shown potential in preclinical studies to enhance efficacy in treating oncology patients, while plans for clinical trials are set for 4Q 2026. Akari continues to generate data to validate its innovative approach among other undisclosed targets.
Read more →Akari Therapeutics has released its latest CEO Corner segment, featuring insights from CEO Abizer Gaslightwala. The segment focuses on the company's advancements in antibody drug conjugates (ADCs), particularly its novel PH1 payload which disrupts RNA splicing in cancer cells. Akari’s next-generation ADC discovery platform aims to create differentiated therapies, with promising preclinical results showcasing significant activity and extended survival. The CEO emphasizes the potential combination of their lead asset AKTX-101 with checkpoint inhibitors to enhance therapeutic effects.
Read more →A general meeting of shareholders for AKTX is scheduled for December 15, 2025. The notice includes links to view and download the proxy form and share buyback agreement. Further details are expected to be provided as the date approaches.
Read more →Akari Therapeutics announced the appointment of Kameel D. Farag as Interim Chief Financial Officer. Farag brings over two decades of experience in biotech finance, having previously held leadership roles at Aspen Neuroscience and Ionis Pharmaceuticals. His expertise is expected to enhance Akari's growth and support the development of its novel antibody drug conjugate platform. Akari focuses on innovative treatments for cancer, with a promising splicing modulation approach expected to improve patient outcomes.
Read more →Akari Therapeutics presented promising data on its novel ADC payload, PH1, at the 40th Annual SITC Meeting. The Trastuzumab-PH1 ADC showed significant anti-tumor effects, particularly when combined with anti-PD1 therapy, leading to a higher rate of complete tumor regressions compared to traditional therapies. This innovative approach could redefine treatment standards in immuno-oncology.
Read more →Akari Therapeutics presented promising data on its novel ADC payload, PH1, at the SITC Meeting. The Trastuzumab-PH1 ADC demonstrated superior tumor regression rates compared to Kadcyla when combined with anti-PD1 therapy. The results indicate a strong immune response and potential for significant advancements in immuno-oncology treatments. A live webcast is scheduled for November 18, 2025, to discuss these findings further.
Read more →Akari Therapeutics has announced the acceptance of its abstract showcasing data on its novel splicing-targeted ADC payload, PH1, which drives immune activation. This data will be presented at the 40th Annual SITC Meeting from November 5-9, 2025. The findings indicate that the PH1 ADC shows enhanced efficacy compared to traditional ADCs, particularly in combination with checkpoint inhibitors.
Read more →Akari Therapeutics has formed a Scientific Advisory Board with Dr. Sara Hurvitz as its inaugural member. This strategic move aims to enhance the company's scientific and clinical strategies in oncology. Dr. Hurvitz, a renowned oncologist, will guide the development of novel antibody drug conjugates, particularly targeting areas with high unmet medical needs. Akari's lead candidate, AKTX-101, shows promising preclinical results.
Read more →Akari Therapeutics has launched the CEO Corner platform to provide stakeholders with deeper insights into its corporate developments and pipeline progress. The initiative, led by CEO Abizer Gaslightwala, aims to enhance transparency and engagement by allowing interested parties to ask questions and suggest topics for future discussions. This move underscores Akari's commitment to advancing its innovative antibody drug conjugates targeting cancers with high unmet needs.
Read more →Akari Therapeutics has announced a registered direct offering to sell 3,125,000 American Depositary Shares (ADSs) at $0.80 each, aiming to raise approximately $2.5 million. The proceeds will be utilized for working capital and further research into their antibody drug conjugate, AKTX-101. This candidate targets cancer cells and has shown significant preclinical efficacy.
Read more →Akari Therapeutics has announced a $2.5 million registered direct offering of its American Depositary Shares (ADSs). The offering includes the issuance of warrants and is expected to close around October 16, 2025. Proceeds will be used for working capital and continued research and development, particularly for its novel antibody drug conjugate targeting cancer.
Read more →Akari Therapeutics has filed two new provisional patent applications for its immuno-oncology payload PH1, which is designed to enhance cancer treatment through spliceosome modulation. The patents cover both the novel payload and its combination therapy with other immuno-oncology drugs. These filings aim to strengthen Akari's intellectual property and support its ongoing research efforts in developing innovative antibody drug conjugates.
Read more →Akari Therapeutics has filed two provisional patent applications for its novel immuno-oncology payload, PH1, which utilizes a spliceosome modulating mechanism. These patents aim to protect Akari's intellectual property and enhance its ADC platform's therapeutic potential. The company plans to present its findings at the upcoming SITC Congress, highlighting the promising synergy of PH1 with checkpoint inhibitors.
Read more →Akari Therapeutics has announced that its abstract has been accepted for oral presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. The presentation will focus on their novel splicing-targeted ADC payload, which aims to drive immune activation and enhance therapeutic potential. The meeting will take place from November 5-9, 2025, in National Harbor, MD.
Read more →Akari Therapeutics announced promising preclinical data for its ADC payload, PH1, which targets the AR-V7 receptor linked to hormone refractory prostate cancer. The data indicates that PH1 can suppress AR-V7 expression and shows efficacy in both resistant and sensitive cancer models. The company aims to develop PH1 as a first-line or second-line therapy for prostate cancer, addressing a significant unmet medical need.
Read more →Akari Therapeutics has filed a provisional patent application for its antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1, aimed at treating cancer. This new patent application advances the company's proprietary position in alternative splicing modulation, which is critical for disrupting cancer cell survival. The PH1 payload has shown potential in preclinical models to induce cancer cell death while activating immune responses. This development is expected to expand Akari's ADC portfolio and may lead to innovative cancer therapies.
Read more →Akari Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Abizer Gaslightwala will lead the presentation, and the company will also hold one-on-one meetings with investors. Akari is focused on developing novel antibody drug conjugates, particularly their lead candidate AKTX-101, which shows significant preclinical promise.
Read more →Akari Therapeutics, an oncology biotechnology firm, will take part in the Virtual Investor Closing Bell Series on September 4, 2025. CEO Abizer Gaslightwala will present an overview of the company's innovative antibody drug conjugate (ADC) pipeline, highlighting its novel immuno-oncology payloads. The event allows investors to submit questions, enhancing stakeholder engagement. Akari's lead candidate, AKTX-101, is designed for targeting cancer cells with promising preclinical results.
Read more →Akari Therapeutics, a biotechnology company focusing on antibody drug conjugates for cancer treatment, will present at the Webull Financial Corporate Connect Webinar Series from August 19-21, 2025. The presentation will be led by CEO Abizer Gaslightwala and will discuss their innovative ADC platform, particularly the novel payload PH1. This technology has demonstrated potential in inducing cancer cell death and is poised for further development. Akari's lead treatment, AKTX-101, shows promising preclinical results and potential synergy with other cancer therapies.
Read more →Akari Therapeutics is advancing its research on the PH1 antibody drug conjugate payload, aimed at targeting key oncogenic drivers in cancer. The company highlights preclinical data suggesting PH1 can both induce cancer cell death and stimulate the immune system. Upcoming preclinical results are expected by year-end, which could further validate PH1's efficacy against critical cancer drivers. The company aims to utilize PH1 to improve oncology therapies significantly.
Read more →Akari Therapeutics participated in the 'What’s Your Story' Summer Spotlight On-Demand Conference, where CEO Abizer Gaslightwala shared his journey and commitment to the company's development programs. Akari is focused on creating novel antibody drug conjugates (ADCs) for cancer treatment, including their lead candidate AKTX-101, which targets the Trop2 receptor. The innovative drug delivery system utilizes a unique payload, PH1, which shows potential in preclinical studies for extending survival compared to traditional therapies. The on-demand video of the conference is accessible on their website.
Read more →Akari Therapeutics announced participation in a Virtual Investor segment discussing its newly granted India Patent No. 562,919 for Thailanstatin Analogs. This patent covers their innovative immuno-oncology payload, PH1, and ADC technology. CEO Abizer Gaslightwala highlighted the potential applications of this technology in treating various cancers, emphasizing the efficacy of their lead candidate, AKTX-101.
Read more →Akari Therapeutics recently highlighted its newly granted India patent during a virtual investor segment. The patent, titled 'Thailanstatin Analogs,' pertains to the company's immuno-oncology technology, including the PH1 payload and its unique linkers. CEO Abizer Gaslightwala emphasized the implications of this patent for the company's ADC developments. Akari's lead candidate, AKTX-101, has shown promising preclinical results, indicating its potential in cancer treatment.
Read more →Akari Therapeutics has announced the granting of a patent for its novel antibody drug conjugate (ADC) immuno-oncology payload, PH1, in India. This patent, which covers claims for the PH1 payload and its associated technologies, positions Akari to further expand its intellectual property in a market with a rapid increase in cancer cases. The company believes that PH1 could significantly improve therapeutic outcomes by activating the immune system and targeting cancer cells effectively. The patent complements Akari’s existing R&D portfolio and underscores their commitment to advancing innovative cancer therapies.
Read more →Akari Therapeutics has announced its 2025 Annual General Meeting (AGM) scheduled for June 30, 2025, in London. Shareholders will vote on several resolutions, including the approval of the directors' remuneration report and the re-election of board members. The board recommends voting in favor of all resolutions to promote the company's success and shareholder interests.
Read more →Akari Therapeutics has announced the release of a new "Meet the Team" video featuring Mark F. Kubik, who has recently been appointed as Head of Business Development for Oncology. This initiative aims to provide insight into the company's leadership and advancements in its oncology-focused research. Akari is developing innovative antibody drug conjugates, particularly its lead candidate, AKTX-101, which has shown preclinical promise in targeting cancer cells. The video can be accessed on the company's website under the Investors section.
Read more →Akari Therapeutics, a biotechnology company focused on oncology, announced that President and CEO Abizer Gaslightwala will present at the upcoming LIVE! with Webull Corporate Connect virtual investment webinar on May 29, 2025. The company is known for developing innovative payload antibody drug conjugates, particularly its lead candidate AKTX-101, which targets the Trop2 receptor on cancer cells. AKTX-101 has demonstrated promising preclinical results, indicating its potential to improve treatment outcomes through a novel mechanism. This webinar may further enhance Akari's visibility within the biotech investment community.
Read more →Akari Therapeutics reported its first quarter 2025 financial results, highlighting advancements in its antibody drug conjugate (ADC) pipeline targeting cancer. The company appointed Mark Kubik as Head of Business Development, enhancing its oncology expertise. Despite a net loss of $3.7 million, Akari continues to focus on developing its lead asset, AKTX-101, and exploring strategic partnerships.
Read more →Akari Therapeutics announced its first quarter 2025 financial results, reporting a net loss of approximately $3.7 million. The company is advancing its novel Antibody Drug Conjugates (ADCs) with promising preclinical data and has appointed a seasoned leader in oncology to enhance its business development efforts. Akari's lead ADC, AKTX-101, continues to show significant potential in targeting various cancer tumors, and the company is actively pursuing strategic partnerships to bolster its research initiatives. Notably, the company secured additional funding to support its ADC platform.
Read more →Akari Therapeutics has appointed Mark F. Kubik as Head of Business Development for Oncology. With over 25 years of experience in the industry, Kubik is expected to drive the company's efforts in advancing its novel antibody drug conjugate platform, particularly the lead asset AKTX-101. His background in establishing successful partnerships will be crucial as Akari aims to leverage its innovative technology in the ADC market.
Read more →Akari Therapeutics has appointed Mark F. Kubik as the new Head of Business Development for Oncology. With over 25 years of experience and a strong track record in oncology therapeutics, Kubik is expected to leverage his expertise to advance Akari's proprietary antibody drug conjugate (ADC) platform. The company aims to maximize opportunities in the growing ADC market. The lead asset, AKTX-101, has potential as a first-in-class treatment targeting various solid tumors.
Read more →Akari Therapeutics has released a corporate update video featuring its newly appointed CEO, Abizer Gaslightwala. He outlines his vision for the company, emphasizing their innovative approach in developing bi-functional antibody drug conjugates (ADCs) aimed at cancer treatment. Akari's lead candidate, AKTX-101, showcases a unique mechanism intended to improve efficacy and reduce off-target toxicity compared to existing therapies. The company's focus on advancing its pipeline positions it well for future growth in the biopharma sector.
Read more →Akari Therapeutics reported its financial results for 2024, highlighting a successful merger with Peak Bio Inc. and advancements in its lead program, AKTX-101, for cancer treatment. The company is focusing on developing next-generation antibody drug conjugates and has appointed new leadership to drive future growth. Despite an increase in net losses, Akari's cash reserves are projected to sustain operations through September 2025.
Read more →Akari Therapeutics reported its fiscal year 2024 financial results, highlighting progress in developing next-generation precision Antibody Drug Conjugates (ADCs) for cancer treatment. The company has successfully merged with Peak Bio Inc. and is advancing lead candidate AKTX-101, which shows potential to mitigate current ADC limitations. Despite a rise in net losses due to merger-related costs, Akari anticipates sufficient cash reserves to continue operations through September 2025. Management has also made strategic leadership appointments to support ongoing initiatives in their therapeutic pipeline.
Read more →Akari Therapeutics announced the appointment of Abizer Gaslightwala as the new President and CEO, effective April 21, 2025. Gaslightwala, who has a notable history in the biotechnology sector, including roles at Jazz Pharmaceuticals and other major companies, is expected to bring strategic leadership to Akari as it focuses on its next-generation antibody drug conjugates (ADCs) for cancer treatment. Current CEO Samir R. Patel will remain on the Board of Directors, ensuring continuity as the company embarks on its new direction under Gaslightwala's stewardship.
Read more →Akari Therapeutics has successfully completed a private placement financing, raising approximately $7.6 million in gross proceeds from existing shareholders and insiders. The funds will be utilized for investments in the company's novel spliceosome inhibitor payload ADC technology and to seek license partners for its TROP-2 ADC program. The anticipated closing date for the placement is March 5, 2025, and investors are expected to acquire unregistered American Depository Shares for the offering.
Read more →Akari Therapeutics participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO Dr. Samir Patel discussed key reasons for investor interest in the company. The firm focuses on developing bi-functional antibody drug conjugates for cancer treatment, including its lead candidate, AKTX-101. This drug targets the TROP2 receptor and may offer advantages over current therapies. The on-demand webcast is available for further insight into the company's strategies and developments.
Read more →Akari Therapeutics has announced its participation in the Webull Corporate Connect Service platform, aiming to improve communication with shareholders and investors. The platform will serve as an additional source for corporate news, earnings reports, and product updates, emphasizing the company's commitment to transparency. CEO Samir R. Patel highlighted the importance of market awareness and engagement with the growing shareholder base. Akari Therapeutics is known for developing innovative next-generation antibody drug conjugates for cancer treatment.
Read more →Akari Therapeutics has announced its corporate presentation regarding next-generation precision bi-functional antibody drug conjugates. The company highlighted the promising development of its lead candidate, AKTX-101, which shows superior efficacy in preclinical studies. However, Akari emphasized that future performance is uncertain due to a range of risks associated with its merger with Peak Bio, Inc. and the overall market dynamics for ADCs. The company aims to fuel its pipeline with innovative therapies that demonstrate prolonged patient survival and enhanced immune engagement against tumors.
Read more →Akari Therapeutics has announced the appointment of Dr. Samir R. Patel as the Chief Executive Officer, effective December 16, 2024. Dr. Patel, who has been serving as the interim CEO since May 2024, aims to leverage the recent merger with Peak Bio to enhance operations and shareholder value. Additionally, Abizer Gaslightwala has been appointed to the Board of Directors, bringing over 25 years of experience in the biotechnology industry. The leadership changes are part of Akari's strategy to advance its innovative therapies and strengthen its position in the market.
Read more →Akari Therapeutics has appointed Dr. Torsten Hombeck as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck, who previously served in the same role until June 2023, brings over 20 years of experience in the biotechnology sector. His return is aimed at strengthening the company's leadership as it focuses on advancing its innovative ADC platform. Both Dr. Hombeck and Akari's Interim President & CEO expressed optimism about the company's potential to create value for shareholders.
Read more →Akari Therapeutics has announced that it has regained compliance with the Nasdaq Stock Market's listing requirements, curing the previous shareholders equity deficiency. As a result, a previously scheduled hearing before the Nasdaq Hearings Panel has been canceled. The interim CEO, Samir Patel, emphasized the importance of this compliance for maintaining shareholder confidence and the ability to focus on the company's business strategy going forward.
Read more →Akari Therapeutics has successfully completed its merger with Peak Bio, creating a biotechnology company focused on advancing therapies for autoimmune and inflammatory diseases. The merger is supported by $3.2 million in PIPE financing and a $50 million equity line of credit. The combined entity aims to leverage its assets to drive shareholder value and develop new treatment options.
Read more →Akari Therapeutics has successfully completed its merger with Peak Bio, creating a biotechnology company focused on multiple disease therapies. The merger is bolstered by $3.2 million in PIPE financing and a $50 million term sheet for an equity line of credit. The combined entity aims to accelerate development in antibody drug conjugates and treatments for geographic atrophy. However, the company must navigate potential risks related to personnel retention and unforeseen liabilities that may affect future performance.
Read more →Akari Therapeutics has received shareholder approval for its merger with Peak Bio, with 99% of votes in favor. The merger is set to close on November 13, 2024, and aims to strengthen Akari's focus on antibody drug conjugates and geographic atrophy therapies. This merger also addresses Akari's Nasdaq listing concerns.
Read more →Akari Therapeutics has announced that its shareholders overwhelmingly approved the merger with Peak Bio, with approximately 99% support at a recent General Meeting. The merger is set to officially close on November 13, 2024. Post-merger, Akari and Peak Bio will operate as a single entity, targeting advancements in antibody drug conjugate therapies and geographic atrophy treatments. This merger is also expected to address Akari's current listing issues on Nasdaq.
Read more →Akari Therapeutics has announced the effectiveness of Form S-4 for its merger with Peak Bio, allowing them to schedule a General Meeting on November 7, 2024. The SEC approved the merger, which is expected to close in Q4 2024, pending customary conditions and shareholder approvals. The merged entity will continue under the name Akari Therapeutics, Plc with a focus on antibody drug conjugates and geographic atrophy treatments.
Read more →Akari Therapeutics will hold a general meeting of shareholders on November 7, 2024, to discuss several key proposals related to a merger with Peak Bio, including share allotment and the appointment of a new chairman. The board recommends that shareholders vote in favor of the proposals outlined in the joint proxy statement. The meeting will take place in London and will require shareholders to register by November 5, 2024.
Read more →Akari Therapeutics has appointed Rob Bazemore to its Board of Directors, effective September 17, 2024. Bazemore, a seasoned leader in life sciences, will contribute his extensive experience in developing and commercializing therapies, particularly in immunology and oncology. This appointment comes as Akari prepares for its merger with Peak Bio, which aims to enhance its portfolio and shareholder value.
Read more →Akari is a biotechnology company developing novel therapies targeting autoimmune and inflammatory diseases through its lead drug, nomacopan. Recently, it reported positive results for PAS-nomacopan, an advanced formulation of nomacopan aimed at treating geographic atrophy related to age-related macular degeneration. Following a constructive meeting with the FDA, the company plans to submit an Investigational New Drug Application in 2025. Additionally, Akari is prioritizing its pipeline ahead of a merger with Peak Bio, potentially expanding its asset portfolio.
Read more →Peak Bio Inc. has released its consolidated financial statements for the years ended December 31, 2023 and 2022. The audit indicates that the company's financial position shows a substantial increase in liabilities, raising concerns about its ongoing viability as a going concern. Notably, the company reported an increase in its accumulated deficit and significant negative cash flows from operations. Management's future plans and need for additional capital were acknowledged in the statements, illustrating potential challenges ahead.
Read more →Akari Therapeutics reported its second quarter 2024 financial results, highlighting a positive regulatory response from the FDA for its PAS-nomacopan treatment for geographic atrophy. The company raised $7.6 million in financing and appointed Dr. Samir R. Patel as interim CEO. However, it also reported a net loss of $7.6 million and suspended its HSCT-TMA program.
Read more →Akari Therapeutics has announced that it received encouraging Pre-IND feedback from the FDA regarding its investigational drug PAS-nomacopan, aimed at treating geographic atrophy. The feedback clarifies Akari's plans for its upcoming Investigational New Drug Application, including preclinical and manufacturing strategies. Akari successfully produced a full-scale batch of its drug under GMP conditions, facilitating a pathway to submit an IND in 2025. Company executives expressed optimism about the drug's potential to offer clinically significant benefits to patients.
Read more →Akari Therapeutics has reported its financial results for Q2 2024, highlighting key developments including positive FDA feedback for PAS-nomacopan. The company has secured significant funding, raising $7.6 million through a private placement and issuing $1 million in convertible notes. However, Akari also reported a net loss of $7.6 million and announced operational restructuring, which resulted in layoffs and the suspension of certain programs. The company's ongoing merger with Peak Bio is progressing with a target closing date in Q4 2024.
Read more →Akari Therapeutics has announced that its Interim CEO, Dr. Samir R. Patel, will be compensated solely with equity, enhancing alignment with shareholders. His recent investment of $1.25 million reflects strong personal commitment to the company's success. There is a focus on advancing the lead compound nomacopan and merging with Peak Bio. The company emphasizes transparency in this arrangement, aiming to boost shareholder value amidst the uncertainties ahead.
Read more →Akari Therapeutics has announced the successful closing of a private placement financing round, expected to generate approximately $7.6 million in gross proceeds. The upsized financing was met with overwhelming interest from both new and existing investors, indicating confidence in the company's direction. The funds will support Akari's strategic plans and advancements in therapies for autoimmune and inflammatory diseases, as well as facilitate a merger with Peak Bio anticipated to finalize in the third quarter of 2024.
Read more →Akari Therapeutics has announced its Annual General Meeting (AGM) scheduled for June 27, 2024, in London. Key resolutions include the approval of the Board's remuneration report and the re-election of several directors. The Board recommends shareholders vote in favor of all proposals, emphasizing the importance of shareholder participation.
Read more →Akari Therapeutics has reported its first quarter 2024 financial results, highlighting a definitive merger agreement with Peak Bio expected to close in Q3 2024. The company has appointed Samir R. Patel, M.D. as interim CEO and is prioritizing Peak Bio's ADC technology alongside Akari's PAS-nomacopan for geographic atrophy. However, the company is also implementing a significant workforce reduction and has reported a net loss of approximately $5.6 million for the quarter.
Read more →Akari Therapeutics has announced its financial results for Q1 2024, highlighting a definitive merger agreement with Peak Bio expected to close in the third quarter. The merger will prioritize the combined company's focus on antibody-drug conjugate technology and Akari's PAS-nomacopan treatment for geographic atrophy, although it comes amid significant operational restructuring, including a major workforce reduction. A net loss of $5.6 million marks a stark contrast to the prior year's figures, indicating financial challenges ahead. The issuance of convertible notes by investors demonstrates continued support for the company during this transitional phase.
Read more →Akari Therapeutics has appointed Dr. Samir R. Patel as interim CEO following the departure of Rachelle Jacques and Melissa Bradford-Klug. Dr. Patel aims to complete the merger with Peak Bio and prioritize the company's portfolio. This leadership change is expected to lead to cost savings and streamline operations.
Read more →Akari Therapeutics and Peak Bio have completed a portfolio prioritization plan as they prepare for their merger. The focus will be on Peak's ADC cancer therapeutic technology and Akari's PAS-nomacopan for Geographic Atrophy. Leadership believes this strategy will enhance business development opportunities. However, some programs, like HSCT-TMA and PHP 303, are being suspended or discontinued.
Read more →Akari Therapeutics and Peak Bio have announced a joint portfolio prioritization plan following their merger. The combined entity will focus on Peak's ADC cancer therapeutic platform and Akari's PAS-nomacopan for Geographic Atrophy. Leadership of both companies believes that this strategy will enhance business development opportunities and funding for important programs. However, the plan includes the suspension of specific clinical studies and the discontinuation of some programs, indicating a shift in resource allocation.
Read more →Akari Therapeutics has announced that it will present new pre-clinical data on its investigational long-acting PAS-nomacopan at the ARVO 2024 Annual Meeting in Seattle. The presentation will focus on the drug's effects on electroretinography testing within a blue light model. PAS-nomacopan is being developed as a potential treatment for geographic atrophy and is nearing the end of its pre-clinical development phase. Akari's pipeline includes other important designations for their lead asset, nomacopan, which targets several serious conditions.
Read more →Akari Therapeutics reported its full-year 2023 financial results, highlighting key developments and a merger agreement with Peak Bio Inc. expected to enhance their pipeline. The company continues to develop nomacopan, a drug potentially applicable for treating pediatric HSCT-TMA, while maintaining promising financial metrics despite the challenging biotech landscape. Akari aims to strategically assess its pipeline post-merger and leverage orphan drug designations to advance its programs. Nonetheless, significant financial losses and reliance on private investments raise some concerns.
Read more →Akari Therapeutics and Peak Bio have announced a definitive agreement to merge in an all-stock transaction, with both companies operating under the Akari Therapeutics name post-merger. The combination will enhance the pipeline, incorporating Peak's innovative antibody drug conjugate toolkit alongside Akari's ongoing developmental projects. The merger, expected to close in late Q2 2024, will involve equal equity ownership for both companies' shareholders and aims to leverage their respective strengths in biopharmaceutical developments targeting autoimmune diseases and oncology.
Read more →Akari Therapeutics has successfully completed a private placement financing, raising around $2 million from existing investors, including Chairman Dr. Ray Prudo and Director Samir R. Patel. The financing involved the issuance of nearly 948,000 unregistered American Depository Shares at a purchase price of $2.11 each. This funding will aid the company in its ongoing development of therapies, including its lead asset, nomacopan, aimed at treating autoimmune and inflammatory conditions.
Read more →Akari Therapeutics, a late-stage biotechnology company, announced its participation in the Biotech Showcase 2024, where President and CEO Rachelle Jacques will present an overview of the company. The event will be held in San Francisco from January 8-10, 2024, alongside the J.P. Morgan Healthcare Conference. Akari's lead drug, nomacopan, is being developed for autoimmune diseases and has received multiple FDA designations for pediatric applications. The company will also engage in one-on-one meetings during the conference.
Read more →Akari Therapeutics has appointed Dr. Samir R. Patel to its Board of Directors, bringing extensive experience in life sciences and a history of successful startups. Dr. Patel, a long-time investor in Akari, aims to support the development of the company's lead asset, nomacopan, which is currently in a Phase 3 clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy. His expertise is expected to bolster Akari's strategic direction at a critical juncture.
Read more →Akari Therapeutics has appointed Dr. Samir R. Patel to its Board of Directors, bringing valuable expertise from his extensive background in life sciences and biotechnology. Dr. Patel is known for his successful ventures in the industry and has been a long-term investor in Akari. This strategic appointment is expected to support the advancement of the company's lead asset, nomacopan, which is currently in clinical development for various autoimmune diseases. Akari is focused on enhancing its pipeline while navigating the complexities of drug development.
Read more →Akari Therapeutics presented positive pre-clinical results for long-acting PAS-nomacopan as a treatment for geographic atrophy at the 4th Annual Dry AMD Therapeutic Development Conference. The company plans to submit an IND in 2024 to initiate Phase 1 clinical trials. The treatment aims to reduce injection frequency and associated risks compared to existing therapies.
Read more →Akari Therapeutics announced progress in the development of long-acting PAS-nomacopan for geographic atrophy (GA) during the 4th Annual Dry AMD Therapeutic Development Conference. The presentation showcased improvements in creating a treatment with longer intervals between injections, aiming to reduce risks associated with current therapies. The company plans to move into clinical trials in 2024, supported by advancements in manufacturing processes.
Read more →Akari Therapeutics will present a poster on its long-acting PAS-nomacopan for treating geographic atrophy due to dry age-related macular degeneration at an upcoming conference. The presentation will showcase the drug's development as a bispecific inhibitor targeting complement C5 and leukotriene B4. The aim is to offer a longer dose interval between injections and mitigate risks associated with existing treatments. Akari's lead asset, nomacopan, is already in clinical trials for other indications and has received FDA designations for pediatric use.
Read more →Akari Therapeutics reported its financial results for the first half of 2023, highlighting progress in its clinical pipeline. The company is preparing to initiate Phase 3 trials for nomacopan in treating pediatric and adult HSCT-TMA and is advancing PAS-nomacopan towards trials for geographic atrophy. Notably, Akari received orphan drug designation from the European Commission and strengthened its executive team with key appointments. With cash reserves and new funding opportunities, the company is positioned for significant developments in the near future.
Read more →Akari Therapeutics, PLC reported its financial results for the six months ending June 30, 2023, highlighting a net loss of approximately $2.99 million. The company also noted a significant accumulated deficit of $220.45 million and current liabilities that exceed assets. Despite some positive cash flow from financing activities, concerns over liquidity and the ability to sustain operations in the near term persist. The financial statements indicate an ongoing challenge to attract sufficient capital for future development efforts.
Read more →Akari Therapeutics, a late-stage biotechnology company, announced its participation in the Emerging Growth Conference scheduled for October 4-5, 2023. President and CEO Rachelle Jacques will present an overview of the company's lead asset nomacopan, highlighting its role in treating autoimmune and inflammatory diseases. The company has received several designations from the FDA for nomacopan, which is currently being evaluated in clinical trials. However, challenges exist regarding regulatory approvals and potential market size for their products.
Read more →Akari Therapeutics has secured $2 million in private placement financing from existing investors, including its chairman and CEO. Additionally, the company received a $2.5 million U.K. R&D tax credit. The financing involves unregistered American Depository Shares and is expected to close on September 22, 2023. Akari is focused on developing therapies for autoimmune and inflammatory diseases, particularly nomacopan for pediatric HSCT-TMA.
Read more →Akari Therapeutics has announced a successful private placement financing that will raise approximately $2 million. This investment comes from existing investors, including prominent company officials such as the Chairman and CEO. Additionally, the company received a U.K. research and development tax credit worth $2.5 million, enhancing its financial stability. The financing involves the issuance of unregistered American Depository Shares at a purchase price of $3.30 each, with expected closing set for September 22, 2023, pending customary conditions. The funds will support Akari's ongoing development of therapies for autoimmune and inflammatory diseases.
Read more →Akari Therapeutics will host a virtual webinar on October 19, 2023, to discuss HSCT-TMA and the potential of its investigational therapy, nomacopan. Featuring experts from children's hospitals and universities, the event aims to address the significant unmet needs in patient care for HSCT-TMA. Akari is currently conducting Phase 3 clinical trials for nomacopan as a treatment option for both pediatric and adult patients.
Read more →Akari is advancing its development of PAS-nomacopan, a treatment aimed at geographic atrophy (GA) that could significantly reduce the need for frequent eye injections. Current treatments often require multiple injections, which can lead to complications such as infection and glaucoma. The new therapy aims to limit the frequency to four or fewer doses annually.
Read more →The article discusses the burdens faced by patients undergoing treatments for geographic atrophy (GA). These treatments require monthly or bi-monthly needle injections into the eye, leading to significant fear and discomfort. Dr. Elias Reichel provides insights on these challenges, highlighting the disruptions to patients' lives caused by the treatment regimen.
Read more →The article discusses Geographic Atrophy (GA), a condition that threatens sight by causing loss of central vision and other visual impairments. Dr. Elias Reichel shares insights on GA, emphasizing its impact on reading speed and night vision. The article underscores the importance of awareness and understanding of this condition.
Read more →Akari Therapeutics has announced that it has regained compliance with Nasdaq's minimum bid price requirement after its American Depository Shares (ADSs) closed at $1.00 or more for ten consecutive business days. The company continues to develop nomacopan, an investigational therapy for autoimmune diseases, and has received various designations from the FDA for its treatment of pediatric conditions. However, Akari faces several operational and regulatory challenges that could impact its future prospects.
Read more →Akari Therapeutics announced that it has regained compliance with Nasdaq's minimum bid price requirement, with its American Depository Shares closing above $1.00 per share for ten consecutive days. This compliance allows Akari to continue trading on the Nasdaq Capital Market under the ticker AKTX. The company is actively developing therapies for autoimmune and inflammatory diseases, with its lead asset, nomacopan, in clinical trials for severe pediatric conditions. The firm has received important FDA designations for nomacopan, reflecting its potential as a treatment option.
Read more →Akari Therapeutics has announced the establishment of its U.S. headquarters office in Boston's Seaport area to support its expanding operations. This move coincides with the upcoming enrollment for two registrational Phase 3 clinical trials for nomacopan, aimed at treating pediatric and adult patients with thrombotic microangiopathy. The trials are expected to begin in late 2023 and 2024, respectively, with additional clinical research on PAS-nomacopan anticipated in geographic atrophy. Akari aims to leverage Boston's biotech resources to enhance its capabilities and advance its clinical programs.
Read more →Akari Therapeutics, Plc announced a change in the ratio of its American Depositary Shares (ADSs) from 100 ordinary shares to 2,000 ordinary shares, effective August 17, 2023. This adjustment is aimed at regaining compliance with Nasdaq's minimum bid price requirement. Although the underlying ordinary shares remain unchanged, the company cautions that it cannot assure the future performance of the ADS price. The exchange for new ADSs will be managed by Deutsche Bank, and any fractional shares will be aggregated and sold with proceeds distributed to ADS holders.
Read more →Akari Therapeutics, Plc has announced a change in the ratio of its American Depositary Shares (ADSs) from one ADS per hundred ordinary shares to one ADS per two thousand ordinary shares. This adjustment is intended to secure compliance with Nasdaq's minimum bid price requirement. Each ADS holder will be required to exchange twenty of their existing ADSs for one new ADS under the new ratio. Deutsche Bank will manage the exchange process, while Akari cannot guarantee the future pricing performance of the ADS.
Read more →Akari Therapeutics has appointed Beth-Anne Lang as Senior Vice President of Regulatory Affairs, effective September 1, 2023. With over 20 years of experience in regulatory strategy and drug development, Lang will play a crucial role as the company approaches key milestones in its Phase 3 clinical trials for nomacopan. Her expertise is expected to enhance Akari's efforts in regulatory filings and interactions with authorities.
Read more →Akari Therapeutics has appointed Beth-Anne Lang as Senior Vice President of Regulatory Affairs, effective September 1, 2023. Lang brings over 20 years of regulatory experience and a history of successful drug approvals, which Akari aims to leverage as it approaches key development milestones. The company is actively advancing its Phase 3 clinical trials for two indications related to HSCT-TMA and preparing for FDA interactions. Lang's expertise is expected to play a crucial role in Akari's mission to bring innovative treatments to patients with unmet medical needs.
Read more →Akari Therapeutics has been granted orphan drug designation for its investigational therapy, nomacopan, by the European Commission for use in hematopoietic stem cell transplantation. This designation follows a positive opinion from the European Medicines Agency and supports ongoing Phase 3 clinical studies of nomacopan. The drug aims to address a critical unmet medical need, as there are currently no approved therapies for HSCT-TMA, a condition which carries a high mortality rate in patients. Akari's nominations include additional designations from the FDA, enhancing its clinical and commercial prospects.
Read more →Akari Therapeutics provided a presentation outlining its forward-looking statements and strategies for nomacopan, a dual-action recombinant protein. The company emphasizes its potential for treating various conditions, including COVID-19 related pneumonia. However, Akari acknowledges uncertainties regarding regulatory approvals and funding needs for its operations, as well as clinical trial enrollment challenges. Despite these risks, the clinical prospects for nomacopan have received encouraging recognitions from regulatory authorities.
Read more →Akari Therapeutics has appointed Wendy DiCicco as interim CFO, bringing over 25 years of life sciences experience. DiCicco has previously held significant roles, including CFO for Renovacor and FerGene, and is expected to contribute to Akari's strategic financial management. The company is focused on advancing its lead asset, nomacopan, through critical milestones.
Read more →Akari Therapeutics announced Wendy DiCicco as its interim Chief Financial Officer. With over 25 years of experience in the life sciences sector, DiCicco has previously held CFO roles in various biopharmaceutical firms and led companies through key milestones including IPOs. Her strategic and operational expertise is expected to contribute positively to the company's mission in developing therapies for autoimmune and inflammatory diseases, particularly nomacopan. DiCicco’s appointment aims to strengthen financial oversight as Akari progresses through crucial developmental stages of its pipeline assets.
Read more →Akari Therapeutics is advancing its clinical development of nomacopan for treating hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company plans to start enrollment in a Phase 3 study for pediatric patients by the end of 2023 and for adults in 2024. Nomacopan has received FDA designations that could expedite its approval process, addressing a significant unmet medical need.
Read more →Akari Therapeutics has provided updates on nomacopan's development for pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company plans to begin patient enrollment in a Phase 3 study for pediatric HSCT-TMA by the end of 2023 and is also moving toward a Phase 3 trial for adults. Nomacopan has gained Orphan Drug and Fast Track designations from the FDA, highlighting its potential importance in treating this severe condition that currently lacks approved therapies.
Read more →Akari Therapeutics has selected a long-acting PAS-nomacopan candidate to advance into clinical trials for geographic atrophy (GA). The company plans to submit an IND in the first half of 2024 and begin trials in the second half. Wacker Biotech GmbH will manufacture PAS-nomacopan, which aims to reduce injection frequency and associated risks compared to current GA treatments.
Read more →Akari Therapeutics has announced the selection of a long-acting PAS-nomacopan for geographic atrophy treatment, following extensive pre-clinical work. The chosen version is designed for effective intravitreal injection and aims to reduce patient discomfort with fewer therapy sessions. With an IND submission planned for 2024, Akari is collaborating with Wacker Biotech for manufacturing. This innovative therapy seeks to address significant patient needs and improve compliance in GA treatments.
Read more →Akari Therapeutics has received a positive opinion from the European Medicines Agency (EMA) regarding its application for orphan drug designation for nomacopan, aimed at treating pediatric patients with hematopoietic stem cell transplantation-related thrombotic microangiopathy (HSCT-TMA). This endorsement from the EMA follows an ongoing Phase 3 clinical trial of nomacopan, which is considered to address a critical unmet medical need, as no approved therapies currently exist for this condition. If the designation is granted, it will provide the company with scientific advice tailored for orphan drugs and potential market exclusivity.
Read more →Akari Therapeutics has appointed Wa'el Hashad to its Board of Directors, bringing extensive biopharmaceutical experience. Hashad will serve on both the Audit and Nominating and Governance Committees. His background includes significant leadership roles in companies such as Longeveron and Avanir Pharmaceuticals. Akari is advancing its lead asset, nomacopan, into Phase 3 studies, which may benefit from Hashad's expertise in drug approval and commercialization.
Read more →Akari Therapeutics, Plc has issued a notice regarding its Annual General Meeting scheduled for June 30, 2023, at 75/76 Wimpole Street, London. The meeting will address several key resolutions including the approval of the Directors' Remuneration Report and the re-election of James Hill as a director. Shareholders are encouraged to vote on these resolutions, with a quorum requirement established for the meeting to proceed. The document also highlights the importance of proxies for shareholders unable to attend.
Read more →Akari Therapeutics' presentation includes forward-looking statements about nomacopan, highlighting its potential as a dual-action treatment for various diseases. The company emphasizes its clinical development journey and the challenges faced, including the need for regulatory approvals and funding. Various risks and uncertainties, including competition and market opportunities, are also acknowledged. Despite these hurdles, nomacopan's promising data and designation by the FDA could facilitate its advancement in the market.
Read more →Akari Therapeutics announced its participation in the A.G.P. Virtual Healthcare Conference scheduled for May 23-24, 2023. The company plans to engage in one-on-one investor meetings during the event. Akari is focused on advancing therapies for autoimmune and inflammatory diseases, with its lead asset being nomacopan, which has received multiple designations from the FDA. These developments could enhance its visibility and investor interest in the company's pipeline.
Read more →Akari Therapeutics has reported its full-year 2022 financial results alongside advancements in its lead asset, nomacopan, a dual-mechanism inhibitor. The Phase 3 clinical trial for nomacopan in pediatric HSCT-TMA is progressing, with enrollment for pivotal data collection expected by late 2023. Additionally, pre-clinical developments for a long-acting formulation to treat geographic atrophy are on track for regulatory submissions in 2024. Despite these advancements, the company faces significant financial challenges and ongoing operational costs.
Read more →Akari Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement, allowing it until October 23, 2023, to regain compliance. The company's American Depository Shares will continue trading during this period. Akari's lead asset, nomacopan, is undergoing various clinical programs, including those targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy. Despite this extension, the company faces several risks related to drug development and compliance with financial regulations.
Read more →Akari Therapeutics is set to host a virtual key opinion leader webinar on May 22, 2023, focused on geographic atrophy and the potential of long-acting PAS-nomacopan. Expert Elias Reichel, M.D., from Tufts University, will share insights during the event, which aims to provide an update on the development of nomacopan. The company, recognized for its innovative therapies targeting autoimmune and inflammatory diseases, seeks to address unmet needs in the treatment landscape. Following the presentations, a live Q&A session will allow for further engagement.
Read more →Akari Therapeutics, a late-stage biotechnology company, will attend ARVO 2023 in New Orleans from April 23 to 27. The company aims to engage with researchers and potential partners regarding its lead asset, nomacopan, which is being studied for autoimmune and inflammatory diseases. In addition, Akari is conducting a Phase 3 clinical trial for nomacopan targeted at severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy. The event is expected to attract 10,000 participants from the vision research community.
Read more →Akari Therapeutics announced that a case study on their investigational drug Nomacopan will be presented at the upcoming EBMT meeting in Paris. The study, focused on pediatric HSCT-TMA, is part of ongoing Phase 3 clinical trials. Nomacopan is a bispecific inhibitor currently moving into pivotal Part B of its trial later this year. The company has received Orphan Drug and Fast Track designations from the FDA for this drug.
Read more →Akari Therapeutics has announced a $4 million registered direct offering, with participation from its Board of Directors and CEO. The funds will be used to advance key programs in its pipeline, particularly focusing on its investigational therapy, nomacopan, for severe pediatric conditions. The company plans to close the offering by March 31, 2023, pending customary conditions. This move reflects Akari's commitment to developing therapies for autoimmune diseases while highlighting confidence from its leadership.
Read more →Akari Therapeutics has received regulatory approval from authorities in Poland and the U.K. to use a new, higher-yielding manufacturing process for its investigational drug nomacopan. This third-generation process enhances the final yield by at least five-fold and supports the ongoing Phase 3 clinical trials focused on pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The approval is seen as a significant milestone towards advancing the pivotal trials, which include sites in multiple countries, including the U.S.
Read more →Akari Therapeutics, a clinical-stage biotechnology company, focuses on therapies for autoimmune and inflammatory diseases using its lead product candidate, nomacopan. Nomacopan has dual inhibitory action targeting complement C5 and leukotriene B4 pathways, promising for conditions like pediatric HSCT-TMA. While the company has received orphan drug and Fast Track designations, it faces Nasdaq compliance challenges that could threaten its listing status. Additionally, financial projections indicate potential equity concerns, complicating the company's future efforts.
Read more →Akari Therapeutics announced a late-breaker presentation of a case study from its Phase 3 Part A clinical trial of nomacopan for pediatric HSCT-TMA at the Transplantation & Cellular Therapy Tandem Meetings. The report detailed a 6-year-old patient who received nomacopan treatment and showed significant clinical improvement without any adverse events related to the drug. However, the presentation also highlighted the seriousness of HSCT-TMA, which has an 80% mortality rate in severe cases, indicating the need for further investigation and validation of this potential treatment.
Read more →Akari Therapeutics has presented forward-looking statements regarding its operations and expectations for nomacopan, a novel bispecific recombinant protein aimed at treating hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The drug has shown promise, evidenced by its acceleration into pivotal studies and orphan drug designations. However, the company notes several risks, including the necessity for additional funding and regulatory challenges. As it moves towards further clinical evaluation, uncertainty remains about the drug's commercial viability and the broader market opportunities.
Read more →Akari Therapeutics has announced progress in the pre-clinical development of long-acting PAS-nomacopan as a treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration. The company aims to submit an Investigational New Drug (IND) application next year to enable clinical trials. The innovative treatment leverages PAS technology for extended dosages, potentially reducing the frequency of injections to just a few times a year, which addresses significant patient burdens. This dual mechanism treatment targets both complement C5 and leukotriene B4, factors critical in the pathophysiology of GA and associated conditions.
Read more →Akari Therapeutics announced the acceleration of its Phase 3 clinical trial for nomacopan in pediatric HSCT-TMA, moving into pivotal Part B earlier than anticipated. The company is also initiating a new pipeline program aimed at developing nomacopan for adult HSCT-TMA, highlighting its commitment to addressing the unmet needs in both pediatric and adult populations. Positive feedback from the FDA regarding dosing strategies supports the decision to advance. However, challenges remain, particularly in recruiting patients from the youngest age cohort, which could affect trial outcomes.
Read more →Akari Therapeutics announced that President and CEO Rachelle Jacques will present an overview of the company at Biotech Showcase 2023 on January 9, 2023. The presentation will cover updates on two key pipeline programs, including a Phase 3 clinical trial of nomacopan for severe pediatric HSCT-TMA and a pre-clinical program for long-acting PAS-nomacopan aimed at treating geographic atrophy. Akari has received FDA designations for its lead drug, affirming its commitment to addressing serious medical needs.
Read more →NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Me
Read more →NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Ophthalmology Day at
Read more →Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA NEW YORK and LONDON, November 10, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced thera
Read more →NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Jefferies London Heal
Read more →Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer NEW YORK and LONDON, November 8, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced t
Read more →NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtu
Read more →Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification LONDON, October 28, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today an
Read more →0.000.000.000.005934917123384735238656482266803874631250P1Y00015411575934917123falseP2YP2Y4759731923 AKARI THERAPEUTICS, PLC Quarterly Report For The Period Ended June 30, 2022 Condensed Consolidated Financial Statements Page Condensed Consolidated Balance Sheets as of June
Read more →Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 million Financing supports Akari’s focused pipeline including the Phase 3 Part A clinical trial of nomacopan in severe pediatric hemato
Read more →NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Can
Read more →Akari Therapeutics Announces $12.75 Million Registered Direct Offering NEW YORK and LONDON, September 12, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,
Read more →Akari Therapeutics Narrows NEW YORK and LONDON, August 1, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it is prioritizing two pip
Read more →NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it is prioritizing two pipeline programs. Cash and resour
Read more →Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy NEW YORK and LONDON, July 28, 2022 (GLOBE NEWSWIRE) -
Read more →Four patients have been enrolled in the Phase 3 Part A clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant related (HSCT) thrombotic microangiopathy (TMA); the Part A study is enrolling seven patients Ten of the clinical trial sites across the U.S.
Read more →Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) NEW YORK and LONDON, July 7, 2022 (GLOBE
Read more →Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies NEW YORK and LONDON, June 13, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AK
Read more →Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focu
Read more →Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress NEW YORK and LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on advanced therapies for autoimmune and inflam
Read more →NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American T
Read more →Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology YORK and LONDON, May 10, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company f
Read more →Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atropy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) NEW YORK and LONDON, May 9, 2022 (GLOBE NEWSWI
Read more →NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced new preclinical data published in Fronti
Read more →Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering NEW YORK and LONDON, March 8, 2022 - Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and infl
Read more →Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5) NEW YORK and LONDON, March 2
Read more →Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma NEW YORK and LONDON, February 28, 2022 - Akari Therapeuti
Read more →NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems ar
Read more →Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases and LONDON, January 26, 2022 - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orph
Read more →to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and commercialization NEW YORK and LONDON, Janu
Read more →NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems ar
Read more →Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering NEW YORK and LONDON, December 30, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Read more →December 2021 Combined Inhibition Of Complement & Leukotriene Pathways To Treat Inflammatory Diseases 2 Forward - Looking Statements Certain statements in this presentation constitute contains "forward - looking" statements within the meaning of Section 27 A of the Securities Ac
Read more →Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) enrolling and treating patients New data reveal potential mechanism of actio
Read more →Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia and LONDON, Decem
Read more →NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems ar
Read more →Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye disease Building on early clinical data in atopi
Read more →NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting P
Read more →NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →Akari Therapeutics Announces Private NEW YORK and LONDON, July 7, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases whe
Read more →NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene sy
Read more →Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-T
Read more →Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid NEW YORK and LONDON, April 28, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune
Read more →NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announc
Read more →Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress NEW YORK and LONDON, April 20, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmun
Read more →Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) NEW YORK and LONDON, April 12, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
Read more →Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the developmen
Read more →Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis NEW YORK and LONDON, February 25, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX), a
Read more →Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease NEW YORK and LONDON, February 1 , 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to
Read more →NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems ar
Read more →Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) NEW YORK and LONDON, December 11, 2020 - Akari Therapeut
Read more →Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) meetings earlier in the year. Phase III study in severe pedi
Read more →Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease NEW YORK and LONDON, December 3, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on inno
Read more →Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo-controlled study using nomacopan for treatment
Read more →Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia NEW YORK and LONDON, October 6, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
Read more →Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid NEW YORK and LONDON, October 1, 2020 - Akari Therapeutics, P
Read more →NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →NEW YORK and LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems a
Read more →International clinical development program of nomacopan for the potential treatment of COVID-19 pneumonia announced Pivotal Phase III study in patients with bullous pemphigoid (BP) expected to start H1 2021 following recent successful end-of-Phase II meeting with FDA Enrollment
Read more →AKARI THERAPEUTICS, PLC Quarterly Report For the Period Ended Condensed Consolidated Financial Statements Page Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019 1 Condensed Consolidated Statements of Comprehensive Loss for the Three a
Read more →Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia NEW YORK and LONDON, August 31, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a Phase III biopharmaceutical company focused on innovative the
Read more →Therapeutics Announces Successful End-of-Phase II Meeting With FDA Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan YORK and LONDON, August 12, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative t
Read more →Akari Therapeutics Announces Appointment of Chief Financial NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therap
Read more →Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC NEW YORK and LONDON, July 1, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ:AKTX), a biopharmaceutical company focused on th
Read more →Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval Preparing for pivotal study in bullous pemphigoid (BP) following recent completion of successful Phase II study Positive EMA opin
Read more →Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid NEW YORK and LONDON, May 21, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
Read more →NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated
Read more →Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in Bullous Pemphigoid Disease Area Index (BPDAI) score Nomacopan has potential to
Read more →Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients NEW YORK and LONDON, May 1, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to tr
Read more →Akari Therapeutics Reports Fourth Quarter Financial Results and Business Highlights Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date NEW YORK and LONDON, March 31, 2020 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical com
Read more →Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement NEW YORK and LONDON, March 4, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator
Read more →Akari Therapeutics, Plc Announces YORK and LONDON, February 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leuk
Read more →Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases NEW YORK and LONDON, January 27, 2020- A
Read more →Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study All patients treated with nomacopan have achieved the primary endpoint of transfusion independence NEW YORK and LONDON, January 10, 2020 - Akari Therapeutics, Pl
Read more →Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND NEW YORK and LONDON, December 23, 2019 - Akari Therapeutics, Plc (Nas
Read more →Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100%
Read more →Revised Press Release Akari Therapeutics Reports Revised Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress NEW YORK and LONDON, November 27, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeuti
Read more →- New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - Clinical progress across our target conditions Phase II BP dat
Read more →Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase NEW YORK and LONDON, October 14, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX)
Read more →Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress NEW YORK and LONDON, October 10, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therape
Read more →NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are impl
Read more →Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid NEW YORK and LONDON, September 13, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator
Read more →September 2019 Investor Presentation Copyright Akari Therapeutics, Plc - 2019 2 Disclaimers Certain statements in this presentation constitute contains "forward - looking" statements within the meaning of Section 27A of th e Securities Act of 1933 and Section 21E of the Securiti
Read more →NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are impl
Read more →Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) NEW YORK and LONDON, August 30, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on
Read more →- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019 Phase I/II clinical study in patients with moderate-to-severe atopic keraconjunctivitis (AKC) announced June 2019 Fur
Read more →Receives FDA Fast Track Designation for Nomacopan for Paediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy NEW YORK and LONDON, August 14, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics t
Read more →announces new data demonstrating synergistic benefits of nomacopan's bifunctional C5 and LTB4 inhibitory activity in pemphigoid NEW YORK and LONDON, August 9, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat
Read more →NEW YORK and LONDON, July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today
Read more →Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering NEW YORK and LONDON, June 28, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the
Read more →Akari Therapeutics' Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC) NEW YORK and LONDON, June 19, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on
Read more →AKARI THERAPEUTICS PLC CONSOLIDATED ANNUAL REPORT AND FINANCIAL Registered Number: 05252842 AKARI THERAPEUTICS PLC CONSOLIDATED ANNUAL REPORT AND FINANCIAL FOR THE YEAR ENDED 31 DECEMBER 2018 C ONTENTS Page Officers and professional advisers 1 Directors' report 2 - 3 Strate
Read more →Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP and AKC trials anticipated in 2019 Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thro
Read more →leukotriene B4 pathway and/or complement C5 via dual-functional recombinant coversin(nomacopan) in Experimental Autoimmune Uveitis (EAU) Mali Eskandarpour1, XiaozheZhang1, GrazynaGalatowicz1, Miles Nunn2,3, Wynne Weston-Davies2, Virginia Calder1 1Institute of Ophthalmology, Lon
Read more →Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases NEW YORK and LONDON, April 26, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innov
Read more →Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid NEW YORK and LONDON, April 23, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmun
Read more →Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights NEW YORK and LONDON, April 23, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory di
Read more →Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting NEW YORK and LONDON, March 27, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative the
Read more →FDA Meeting Outlines Path Ahead for Akari Therapeutics's Coversin Stem Cell Transplant-Related Thrombotic Microangiopathy NEW YORK and LONDON, March 13, 2019 - Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orpha
Read more →Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin NEW YORK and LONDON, November 30, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammat
Read more →Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit NEW YORK and LONDON, November 15, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflamma
Read more →Four ongoing clinical trial programs Two clinical programs expected to report initial data in first quarter 2019 Long-term clinical study continues to yield encouraging safety data NEW YORK and LONDON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a
Read more →October 2018 Investor Presentation Copyright Akari Therapeutics, Plc - 2018 2 Disclaimers Certain statements in this presentation constitute contains "forward - looking" statements within the meaning of Section 27A of th e Securities Act of 1933 and Section 21E of the Securities
Read more →Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari's Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity
Read more →Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON, September 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ:AKTX), a biopharmaceutical company focused
Read more →Announces Second Quarter 2018 Financial Results and Business Highlights Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON, September 27, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company foc
Read more →NEW YORK and LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases w
Read more →Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin's bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways NEW YORK
Read more →Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials NEW YORK and LONDON, August 17, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercia
Read more →0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 0 10 20 30 40 50 60 70 80 90 Median and range LDH x ULN Days since first dose of Coversin 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 0 10 20 30 40 50 60 70 80 90 Median and range LDH x ULN Days since first dose Coversin Results of COBALT, a Phase II clinical
Read more →NEW YORK and LONDON, June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces it will be p
Read more →Akari Therapeutics Receives Notice Related to Delay in 20-F Filing NEW YORK and LONDON, May 21, 2018 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune an
Read more →Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress NEW YORK and LONDON, March 21, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of
Read more →NEW YORK and LONDON, March 16, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the Co
Read more →NEW YORK and LONDON, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, t
Read more →Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials NEW YORK and LONDON, February 6, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or "the Company"), a biopharmaceutical company focus
Read more →Therapeutics Strengthens Board with Two Senior Industry Appointments 23, 2018 NEW YORK and LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or "the Company"), a biopharmaceutical company focused on the development and commercialization o
Read more →Akari Therapeutics Announces Phase II COBALT trial of CoversinTM in Patients with PNH Met the Primary Endpoint NEW YORK and LONDON, December 8, 2017 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of innova
Read more →Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original dosing regimen. The Day 28 Endpoint was less than or equal to 1.5 x ULN for all three patients. The new dosing regimen
Read more →NEW YORK and LONDON, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, plans to webcast an analyst
Read more →NEW YORK and LONDON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that it has
Read more →NEW YORK and LONDON, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that it inte
Read more →Akari Therapeutics Announces Further Clinical Progress NEW YORK and LONDON, October 11, 2017 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosa
Read more →Akari Therapeutics Announces Regulatory Progress Following Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON, September 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercializ
Read more →Akari Therapeutics Announces Appointment of David Horn Solomon NEW YORK and LONDON, August 21, 2017 - Akari Therapeutics is pleased to announce that Dr David Horn Solomon will be appointed as the company's new chief executive officer (CEO), effective "I am very pleased that Da
Read more →NEW YORK and LONDON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson, Chief Operations Officer, and Dr. Wynne Weston-Davies, Medical Director, will present at t
Read more →AKARI THERAPEUTICS PLC Company No. 05252842 ARTICLES OF ASSOCIATION The Companies Act 2006 Public Company Limited by Shares 1. Preliminary 1 2. Liability of members 3 3. Share capital and variation of rights 3 4. Certificates and shares 5 5. Uncertificated Shares 6 6. Calls
Read more →July 2017 NASDAQ: AKTX Copyright Akari Therapeutics, Plc 2017 1 Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of t
Read more →NEW ORLEANS, July 10, 2017 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (Nasdaq:AKTX). In
Read more →NEW ORLEANS, June 30, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit
Read more →Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association NEW YORK and LONDON, June 23, 2017 -- Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today a
Read more →NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Akari Therapeutics, Plc securities (NASDAQ:AKTX) from March 30, 2017 through May 11, 2017, both dates inclusive (the “Class Period”) of the important July 11, 201
Read more →Akari Therapeutics Announces Resignation NEW YORK and LONDON, May 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced the resignation of Gur Roshwalb, the Company's Chief Executive Office
Read more →NEW ORLEANS, LA--(Marketwired - May 19, 2017) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action law
Read more →NEW YORK, May 12, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities
Read more →Akari Therapeutics Announces Edison's Withdrawal of Edison Report titled "Akari's Coversin matches Soliris in Phase II" NEW YORK and LONDON, April 27, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, rele
Read more →Akari Therapeutics demonstrates positive response with Coversin in ongoing phase 2 PNH trial and in additional clinical targets -Interim Phase 2 PNH data demonstrate positive response with -Phase 3 PNH program expected to commence in 4Q2017 -Data from preclinical aHUS model d
Read more →NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the Jefferies Complement Symposium on April 6, 2
Read more →NEW YORK and LONDON, March 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for Coversin™ for treatment of
Read more →NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will be hosted by memb
Read more →NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 29th Annual ROTH Conference on March 14th, 2
Read more →NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will attend and host meetings at two upcoming conferences. Canaccord Genuity 2017 Rare Di
Read more →January 2017 NASDAQ: AKTX Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27A of the Securit ies Act and Section 21E of the Securities Exchange Act and are usua
Read more →NEW YORK and LONDON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams. In December 2016, Dr. Brihad Abhyankar joined as Head of Clinical Development and
Read more →NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on December 29th, 2016, its Investigational New Drug
Read more →December 2016 NASDAQ: AKTX Copyright Akari Therapeutics, Plc 2016 Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27A of the Securit ies Act and Section 21E of
Read more →-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical data supports once weekly dosing- -Phase II PNH patients identified with data expected 1Q17- -Eculizumab resistant PNH patient treated for over 9 months with Cove
Read more →NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will attend and host meetings at two upcoming conferences. Jeffe
Read more →AKARI PHARMACEUTICALS, Plc Quarterly Report For the Period Ended Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and December 31, 2015 2 Condensed Consolidated Statements of Comprehensive Loss for the Thr
Read more →NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been accepted at the 58th Annual Meeting of the American Society of Hematology in San Diego,
Read more →NEW YORK and LONDON, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment of Robert Ward to its Board of Directors. Mr. Ward brings over twenty-five years of pharmaceutica
Read more →NEW YORK and LONDON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. Gur Roshwalb, Chief Executive Officer, will present at two upcoming investor conferences: Ladenburg Thalmann
Read more →NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted to Akari an Orphan Drug Designation for recombin
Read more →NEW YORK and LONDON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 36th Annual Canaccord|Genuity Growth Conferen
Read more →NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase 2 trial in pat
Read more →NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opi
Read more →July 2016 NASDAQ: AKTX Cautionary Note Regarding Forward - Looking Statements Copyright 2016 Akari Therapeutics Plc 1 Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27A of the Securit ies Act and Section 21E of the
Read more →NEW YORK and LONDON, July 06, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced positive interim data from the first cohort in its Phase Ib trial which demonstrates maintenance of complement in
Read more →NEW YORK and LONDON, June 15, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Dr. Gur Roshwalb, Chief Executive Officer, will participate in a fireside chat and provide an overview of th
Read more →NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief Executive Officer, will present and participate in a question-and-answer session at t
Read more →NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin therapy in an eculizumab resistant paroxysmal nocturnal hemoglobinuria (PNH) patient will
Read more →NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into
Read more →Therapeutics Announces Positive Preliminary Results from First PNH Treated With Coversin NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary res
Read more →NEW YORK and LONDON, March 01, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that Gur Roshwalb, M.D., Chief Executive Officer, will present and participate in a question-and-answer sessi
Read more →NEW YORK and LONDON, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that members of its management team will participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day on
Read more →NEW YORK and LONDON, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase IB multiple
Read more →NEW YORK and LONDON, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One
Read more →NEW YORK and LONDON, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update from its 28 day non-human primate (NHP) safety study that Coversin demonstrated complete inhibition of com
Read more →NEW YORK and LONDON, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, provided an update from its 28 day non-human primate (NHP) safety study at the International PNH Interest Group 10th Annual Sc
Read more →ADVISORY, Dec. 04, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq:AKTX), an emerging growth, development-stage biopharmaceutical company focused on orphan and rare autoimmune and inflammatory diseases, will visit the Nasdaq MarketSite in Times Square. In honor of the o
Read more →NEW YORK and LONDON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that new data on Coversin efficacy in eculizumab resistant patients will be presented at the 57th American Soc
Read more →IMMUNO PHARMACEUTICALS SA As of and for the Six Months Ended June Combined and Consolidated Financial Statements Combined and Consolidated Balance Sheets at June 30, 2015 (Unaudited) and December 31, 2014 2 Unaudited Combined and Consolidated Statements of Comprehensive Loss f
Read more →SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2015 (Exact Name of Registrant as Specified England and Wales 001-36288 98-103
Read more →NEW YORK and LONDON, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a previously announced private placement finan
Read more →Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics NEW YORK and LONDON, September 18, 2015 (GLOBE NEWSWIRE) - Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno
Read more →Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement NEW YORK and LONDON, August 18, 2015 (GLOBE NEWSWIRE) - Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a s
Read more →Celsus Therapeutics Plc (to be renamed Akari Therapeutics Plc) Celsus Therapeutics (CLTX) and Volution Immuno Pharmaceuticals SA July 2015 Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation regarding the proposed business combination t
Read more →Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment NEW
Read more →2014 EQUITY INCENTIVE PLAN specified or unless the context otherwise requires, the following terms, as used in this Celsus Therapeutics PLC 2014 Equity Incentive Plan, have the following meanings: means the committee to which the Board of Directors has delegated the authority
Read more →CELSUS THERAPEUTICS PLC Company number 05252842 Notice of Annual General Meeting THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stoc
Read more →Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs American Depository Shares listed on the NASDAQ Capital Market under the trading symbol "CLTX" YORK, NY AND LONDON, UK - February 5,
Read more →Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ Shares Approved for Listing on the NASDAQ Capital Market Under the Symbol "CLTX" YORK, NY AND LONDON, UK - January 30, 2014 - Celsus Therapeutics Plc (NASDAQ:CLTX)(formerly OTCQB:CLSXD), an emergin
Read more →Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer of Experienced Dermatology CMO to Drive Clinical Advancement of MRX-6 -- YORK and LONDON, October 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development
Read more →Celsus Therapeutics Names Allan Shaw to Board of Directors NEW YORK and LONDON - (GLOBE NEWSWIRE - October 2, 2013) - Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of biopharmaceutical industry
Read more →Celsus Therapeutics Announces $12.5 Million Private Placement NEW YORK, NY AND LONDON, UK, September 19, 2013 -- Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biotechnology company, announced today that it has entered into a securities purchase agre
Read more →Celsus Therapeutics Announces ADR Ticker Symbol Change to NEW YORK, NY AND LONDON, UK, September 16, 2013 (BUSINESS WIRE) -- Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biotechnology company, announced that effective September 16, 2013, the Compan
Read more →CELSUS THERAPEUTICS ANNOUNCES POSITIVE PHASE II INTERIM RESULTS FOR MRX-6 IN THE TREATMENT OF CONTACT DERMATITIS NEW YORK, NY AND LONDON, UK - May 08, 2013 - Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotechnology company, announced today posi
Read more →CELSUS THERAPEUTICS STRENGTHENS BOARD ADDITION OF DERMATOLOGY INDUSTRY VETERAN ROBERT F. DOMAN NEW YORK, NY AND LONDON, UK - May 1, 2013 - Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced the addition of industry veteran Rob
Read more →CELSUS THERAPEUTICS STRENGTHENS BOARD OF DIRECTORS WITH ADDITION OF PHARMA/BIOTECH INDUSTRY VETERAN FREDRIC PRICE NEW YORK, NY AND LONDON, UK - April 30, 2013 - Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced the addition o
Read more →Morria Announces Corporate Trade Name Change to Celsus Therapeutics and The Appointment of Dr. Gur Roshwalb as Chief Executive Officer New York, NY and London, UK - March 5, 2013 -Morria Biopharmaceuticals Plc (OTCQB: MRRBY), an emerging growth, development-stage biotech compa
Read more →Morria Biopharmaceuticals Announces Full Alan Harris, M.D., Ph.D., as Chief Medical NEW YORK (January 23, 2013) Morria Biopharmaceuticals Plc) (the "Company"), an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, non-steroidal an
Read more →